MX2021014246A - Procedimientos y productos intermedios para preparar un inhibidor de btk. - Google Patents
Procedimientos y productos intermedios para preparar un inhibidor de btk.Info
- Publication number
- MX2021014246A MX2021014246A MX2021014246A MX2021014246A MX2021014246A MX 2021014246 A MX2021014246 A MX 2021014246A MX 2021014246 A MX2021014246 A MX 2021014246A MX 2021014246 A MX2021014246 A MX 2021014246A MX 2021014246 A MX2021014246 A MX 2021014246A
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- processes
- sup
- intermediates
- btk inhibitor
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940124291 BTK inhibitor Drugs 0.000 title abstract 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960001507 ibrutinib Drugs 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019087823 | 2019-05-21 | ||
| PCT/EP2020/064123 WO2020234381A1 (en) | 2019-05-21 | 2020-05-20 | Processes and intermediates for preparing a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014246A true MX2021014246A (es) | 2022-01-06 |
Family
ID=70857160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014246A MX2021014246A (es) | 2019-05-21 | 2020-05-20 | Procedimientos y productos intermedios para preparar un inhibidor de btk. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12215110B2 (https=) |
| EP (1) | EP3972977A1 (https=) |
| JP (1) | JP7658916B2 (https=) |
| KR (1) | KR20220011668A (https=) |
| CN (1) | CN113874378A (https=) |
| AU (1) | AU2020278162A1 (https=) |
| BR (1) | BR112021022347A2 (https=) |
| CA (1) | CA3135240A1 (https=) |
| IL (1) | IL288154A (https=) |
| MX (1) | MX2021014246A (https=) |
| WO (1) | WO2020234381A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12450495B2 (en) | 2022-06-13 | 2025-10-21 | International Business Machines Corporation | Neural capacitance: neural network selection via edge dynamics |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2526933T3 (en) * | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| PT2414363E (pt) * | 2009-03-31 | 2014-02-26 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| CA2901510C (en) * | 2013-03-15 | 2022-11-29 | Janssen Pharmaceutica Nv | Processes for preparing ibrutinib derivatives and intermediates thereof |
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| MA41350A (fr) | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| JP6681922B2 (ja) | 2015-02-12 | 2020-04-15 | 上▲海▼度▲徳▼医▲藥▼科技有限公司 | イブルチニブの製造方法 |
-
2020
- 2020-05-20 WO PCT/EP2020/064123 patent/WO2020234381A1/en not_active Ceased
- 2020-05-20 BR BR112021022347A patent/BR112021022347A2/pt unknown
- 2020-05-20 US US17/612,082 patent/US12215110B2/en active Active
- 2020-05-20 EP EP20728440.7A patent/EP3972977A1/en active Pending
- 2020-05-20 MX MX2021014246A patent/MX2021014246A/es unknown
- 2020-05-20 JP JP2021569238A patent/JP7658916B2/ja active Active
- 2020-05-20 KR KR1020217041326A patent/KR20220011668A/ko not_active Withdrawn
- 2020-05-20 AU AU2020278162A patent/AU2020278162A1/en not_active Abandoned
- 2020-05-20 CN CN202080037397.5A patent/CN113874378A/zh active Pending
- 2020-05-20 CA CA3135240A patent/CA3135240A1/en active Pending
-
2021
- 2021-11-16 IL IL288154A patent/IL288154A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3972977A1 (en) | 2022-03-30 |
| KR20220011668A (ko) | 2022-01-28 |
| BR112021022347A2 (pt) | 2022-01-04 |
| AU2020278162A1 (en) | 2021-11-18 |
| IL288154A (en) | 2022-01-01 |
| BR112021022347A8 (pt) | 2021-12-28 |
| US20220204516A1 (en) | 2022-06-30 |
| JP7658916B2 (ja) | 2025-04-08 |
| JP2022533747A (ja) | 2022-07-25 |
| CN113874378A (zh) | 2021-12-31 |
| CA3135240A1 (en) | 2020-11-26 |
| WO2020234381A1 (en) | 2020-11-26 |
| US12215110B2 (en) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230496A (es) | Compuestos heterocíclicos | |
| MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| SG11201906688VA (en) | Novel ester compounds, method for the production thereof and use thereof | |
| SG170794A1 (en) | Process for preparation of hiv protease inhibitors | |
| MX2024002589A (es) | Proceso para sintetizar derivados de naftiridina y compuestos intermedios de los mismos. | |
| GEP20247626B (en) | Industrial process for the preparation of high purity estetrol | |
| MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
| MX377644B (es) | 6.7.beta-epóxidos esteroideos como intermedios químicos. | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| MX2023003173A (es) | Un proceso para la sintesis de compuestos antranilicos de acido/amida e intermedios de los mismos. | |
| MX2023003496A (es) | Un proceso para la sintesis de compuestos antranilicos de acido/amida e intermedios de los mismos. | |
| MX2020013827A (es) | Proceso de preparacion de compuestos triciclicos. | |
| MX2024009760A (es) | Proceso para preparar compuestos de silicio organico. | |
| PH12022550221A1 (en) | Process-scale synthesis of a plasma kallikrein inhibitor | |
| EP4410989A3 (en) | Method for producing heterocyclidene acetamide derivatives | |
| MX2023014962A (es) | Proceso para elaborar derivado de diaril isoxazolina. | |
| MX2021014246A (es) | Procedimientos y productos intermedios para preparar un inhibidor de btk. | |
| MX2013000294A (es) | Intermedios y procedimiento de preparación de un inhibidor específico de la trombina. | |
| DE602004020667D1 (en) | Prostaglandinsynthese | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| PH12021552225A1 (en) | Crystal of heterocyclic amide compound and method for producing same | |
| MX2023005713A (es) | Nuevo proceso para la elaboracion de derivados de tetrazol. | |
| MX2021007945A (es) | Metodos de produccion para compuesto nitroso y compuesto de quinoxalina. | |
| PH12022550529A1 (en) | Magl inhibitor, preparation method and use thereof |